The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(iii)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sanofi Healthcare India Pvt Ltd

7th October 2026 (1) SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”) Corporation Finance Department, Division of Corporate Restructuring, Plot No. C-4A, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 (2) BSE Limited The Secretary Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001 (3) The National Stock Exchange of India Limited The Secretary Exchange Plaza, C-1, Block G, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051 Cc: Mr. Haresh Vala, Company Secretary and Compliance officer- Sanofi India Limited Address: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 Sub: Filing of exemption Report under Regulation 10(7) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (“SAST Regulations”) in respect of the acquisition under Regulation 10(1)(a)(iii) of the SAST Regulations Reference: Target Company: Sanofi India Limited ISIN: INE058A01010: BSE Scrip Code: 500674: NSE Scrip Symbol: Sanofi Dear Sir/Madam, With reference to the abovementioned subject, Sanofi Healthcare India Private Limited, an entity part of the promoter group of Sanofi India Limited (“Target Company”) has acquired 3,500,000 equity shares representing 15.20% of the equity share capital of the Target Company from Hoechst GmbH, a promoter of the Target Company, on 24th September 2026. This acquisition is an inter-se transfer among members of the promoter and promoter group of the Target Company through a block deal mechanism on the Stock Exchange and falls within the exemption provided under Regulation 10(1)(a)(iii) of the SAST Regulations. The aggregate holding of promoter and promoter group before and after the above inter-se transfer remains unchanged. The respective intimations under Regulation 10(5) and 10(6) of the SAST Regulations have already been filed with Stock Exchanges on 17th September 2026 and 28th September 2026, respectively and the same are enclosed as annexures to the Report under Regulation 10(7) of the SAST Regulations. We enclose herewith the Report under Regulation 10(7) of the SAST Regulations in the specified format along with the annexures as required to be given for the said acquisition of the equity shares of the Target Company. The applicable fees of Rs. 1,50,000/- (Rupees One Lakh Fifty Thousand only) plus GST @ 18% of Rs. 27,000/- (Rupees Twenty-Seven Thousand only) aggregating to Rs. 1,77,000/- (Rupees One Lakh Seventy-Seven Thousand only) have been remitted through internet banking transaction no. DCH3BEF1Y9SC36 dated 6th October 2026. We request you to please take the above documents on record. Thanking you. Yours faithfully, For Sanofi Healthcare India Private Limited Neha Pokhrana Company Secretary Membership No.: A40082 Place: Mumbai Encl.: As above Disclosure under Regulation 10(7) - Report to SEBI in respect of any acquisition made in reliance upon exemption provided for in regulation 10(1)(a)(iii) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 1. G eneral Details a. Name, address, telephone no., e-mail of Sanofi Healthcare India Private Limited acquirer(s) {In case there are multiple (“Acquirer”) acquirers, provide full contact details of Address: 2nd Floor, Sanofi House, CTS No. any one acquirer (the correspondent 117-B, L&T Business Park, Saki Vihar Road, acquirer) with whom SEBI shall Powai, Mumbai 400 072 correspond.} Email id: Company-Secretary@sanofi.com Phone No: +91(22) 2803 2000 b. Whether sender is the acquirer (Y/N) Yes c. If not, whether the sender is duly Not Applicable authorized by the acquirer to act on his behalf in this regard (enclose copy of such authorization) d. Name, address, Tel no. and e-mail of Not Applicable sender, if sender is not the acquirer 2. C ompliance of Regulation 10(7) a. Date of Report 7th October 2026 b. Whether report has been submitted to Yes SEBI within 21 working days from the date of the acquisition c. Whether the report is accompanied with Yes, the applicable fees of Rs. 1,50,000/- plus fees as required under Regulation 10(7) GST @ 18% of Rs. 27,000/- aggregating to Rs. 1,77,000/- has been remitted through internet banking transaction no. DCH3BEF1Y9SC36 dated 6th October 2026. Copy of the same is enclosed herewith as Annexure A 3. C ompliance of Regulation 10(5) a. Whether the report has been filed with the Yes, copy of the same is enclosed as Annexure Stock Exchanges where the shares of the B Company are listed, at least 4 working days before the date of the proposed acquisition b. Date of Report 17th September 2026 4. C ompliance of Regulation 10(6) a. Whether the report has been filed with Yes, copy of the same is enclosed as Annexure the Stock Exchanges where the shares of C the Company are listed within 4 working days of the acquisition b. Date of Report 28th September 2026 5. D etails of the Target Company a. Name & address of TC Sanofi India Limited (“Target Company”) Address: Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 b. Name of the Stock Exchange(s) where BSE Limited the shares of the TC are listed The National Stock Exchange of India Limited 6. D etails of the acquisition a. Date of acquisition 24th September 2026 b. Acquisition price per share (in Rs.) Rs. 3,052 per share c. Regulation which would have been Regulation 3(2) read with 3(3) of the Securities triggered an open offer, had the report not and Exchange Board of India (Substantial been filed under Regulation 10(7) (whether Acquisition of Shares and Takeovers) Regulation 3(1), 3(2), 4 or 5) Regulations, 2011 (“SAST Regulations”) d. Shareholding of acquirer/s and PAC Before the After the acquisition individually in TC (in terms of no: & as a acquisition percentage of the total share/voting capital No. of % w.r.t No. of % w.r.t of the TC)(*) Shares total Shares total share share capital capital /voting /voting rights rights of TC of Sanofi Healthcare India Private Limited Nil Nil 3,500,000 15.20 (Acquirer) PAC: 1. Hoechst GmbH (Seller) 13,904,722 60.38 10,404,722 45.18 2. SANOFI 4,865 0.02 4,865 0.02 3. CKW PHARMA EXTRAKT Nil Nil Nil Nil BETEILIGUNGS UND VERWALTUNGS Nil Nil Nil Nil 4. CKW PHARMA EXTRAKT GMBH & Co.KG 5. Future Capital AG Hessen Life Sciences Nil Nil Nil Nil Chemie 6. Sanofi Aventis de Colombia S.A. Nil Nil Nil Nil 7. Sanofi Aventis Deutschland GmbH Nil Nil Nil Nil 8. Starlink Logistics Inc. (SLLI) Nil Nil Nil Nil 9. Aventis Agriculture Nil Nil Nil Nil 10. CARRAIG INSURANCE DAC Nil Nil Nil Nil 11. Sanofi Cathay (Shanghai) Private Nil Nil Nil Nil Equity Investment Fund Partnership (L.P.) Nil Nil Nil Nil 12. Innobio 2 Nil Nil Nil Nil 13. Le Rock Re Nil Nil Nil Nil 14. Limited Liability Company Sanofi Aventis Ukraine Nil Nil Nil Nil 15. Sanofi Aventis del Peru S.A Nil Nil Nil Nil 16. Sanofi Aventis Groupe Nil Nil Nil Nil 17. Sanofi Aventis Korea Co., Ltd. Nil Nil Nil Nil 18. Sanofi Aventis Participations Nil Nil Nil Nil 19. Sanofi Aventis Recherche & Développement Nil Nil Nil Nil 20. Sanofi B.V. Nil Nil Nil Nil 21. Cathay Growth (Quanzhou) Equity Investment Fund L.P Nil Nil Nil Nil 22. Sanofi European Treasury Center Nil Nil Nil Nil 23. Sanofi Foreign Participations B.V. Nil Nil Nil Nil 24. SANOFI GESTION SA Nil Nil Nil Nil 25. SANOFI PASTEUR MERIEUX Nil Nil Nil Nil 26. Sanofi R&D Vaccins Nil Nil Nil Nil 27. Sanofi sp. z.o.o. Nil Nil Nil Nil 28. Sanofi (China) Investment Co. Ltd. 13,909,587 60.40 13,909,587 60.40 TOTAL e. Shareholding of seller/s in TC (in terms Before the After the acquisition of no: & as a percentage of the total acquisition share/voting capital of the TC) (*) No. of % w.r.t No. of % w.r.t Shares total Shares total share share capital capital /voting /voting rights rights of TC of Hoechst GmbH (Seller) 13,904,722 60.38 10,404,722 45.18 7. In formation specific to the exemption category to which the instant acquisition belongs - Regulation 10(1)(a)(iii) a. Provide the names of the [Showing first 8,000 characters — download PDF for full document]